Skip to main content
Erschienen in:

06.04.2019 | Original Research

The Unusual Suspects of the Pancreas—Understanding Pancreatic Acinar Cell Carcinomas and Adenomas

verfasst von: Andreas Minh Luu, Tim Fahlbusch, Johanna Munding, Waldemar Uhl, Chris Braumann

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Acinar cell carcinomas (ACC) and adenomas (ACA) of the pancreas are rare entities. Sufficient knowledge about occurrence and prognosis is scarce.

Methods

A retrospective chart review of our database was performed for all patients who had undergone pancreatic surgery between 2006 and 2018. Results were compared to recent literature findings.

Results

Nine patients were diagnosed with ACC and four patients with ACA of the pancreas in the study period. ACC patients were older and more often male than patients of the ACA group. ACC were mainly localized in the pancreatic head, whereas ACA were more often found in the distal pancreas. Tumor markers are not necessarily elevated, even in case of malignancy.

Conclusions

ACC and ACA are very rare pancreatic tumors. Both entities account for less than 1% of all pancreatic neoplasms. Diagnosis is challenging due to unspecific radiologic features and clinical symptoms. Nevertheless, a patient complaining of abdominal discomfort and an unclear hypodense pancreatic lesion should undergo surgical exploration.
Literatur
1.
Zurück zum Zitat Wang G, Ji L, Qu F-Z, Le Li CC-L, Li Z-B, et al. Acinar cell cystadenoma of the pancreas: a retrospective analysis of ten-year experience from a single academic institution. Pancreatology. 2016;16(4):625–31.CrossRef Wang G, Ji L, Qu F-Z, Le Li CC-L, Li Z-B, et al. Acinar cell cystadenoma of the pancreas: a retrospective analysis of ten-year experience from a single academic institution. Pancreatology. 2016;16(4):625–31.CrossRef
2.
Zurück zum Zitat Singhi AD, Norwood S, Liu T-C, Sharma R, Wolfgang CL, Schulick RD, et al. Acinar cell cystadenoma of the pancreas: a benign neoplasm or non-neoplastic ballooning of acinar and ductal epithelium? Am J Surg Pathol. 2013;37(9):1329–35.CrossRef Singhi AD, Norwood S, Liu T-C, Sharma R, Wolfgang CL, Schulick RD, et al. Acinar cell cystadenoma of the pancreas: a benign neoplasm or non-neoplastic ballooning of acinar and ductal epithelium? Am J Surg Pathol. 2013;37(9):1329–35.CrossRef
3.
Zurück zum Zitat Berner O. Subkutane Fettgewebsnekrose. Virchows Arch path Anat. 1908;193(3):510–8.CrossRef Berner O. Subkutane Fettgewebsnekrose. Virchows Arch path Anat. 1908;193(3):510–8.CrossRef
4.
Zurück zum Zitat Zamboni G, Terris B, Scarpa A, Kosmahl M, Capelli P, Klimstra DS, et al. Acinar cell cystadenoma of the pancreas: a new entity? Am J Surg Pathol. 2002;26(6):698–704.CrossRef Zamboni G, Terris B, Scarpa A, Kosmahl M, Capelli P, Klimstra DS, et al. Acinar cell cystadenoma of the pancreas: a new entity? Am J Surg Pathol. 2002;26(6):698–704.CrossRef
5.
Zurück zum Zitat Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, et al. Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg. 2008;12(6):1061–7.CrossRef Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, et al. Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg. 2008;12(6):1061–7.CrossRef
6.
Zurück zum Zitat Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.CrossRef Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.CrossRef
7.
Zurück zum Zitat Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRef Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRef
8.
Zurück zum Zitat Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRef Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRef
9.
Zurück zum Zitat Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16(9):815–37.CrossRef Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16(9):815–37.CrossRef
10.
Zurück zum Zitat Chaudhary P. Acinar cell carcinoma of the pancreas: a literature review and update. Indian J Surg. 2015;77(3):226–31.CrossRef Chaudhary P. Acinar cell carcinoma of the pancreas: a literature review and update. Indian J Surg. 2015;77(3):226–31.CrossRef
11.
Zurück zum Zitat Bachmann J, Büchler MW, Friess H, Martignoni ME. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer. 2013;65(6):827–33.CrossRef Bachmann J, Büchler MW, Friess H, Martignoni ME. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer. 2013;65(6):827–33.CrossRef
12.
Zurück zum Zitat Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20(24):4673–8.CrossRef Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20(24):4673–8.CrossRef
13.
Zurück zum Zitat Kuopio T, Ekfors TO, Nikkanen V, Nevalainen TJ. Acinar cell carcinoma of the pancreas. Report of three cases. APMIS. 1995;103(1):69–78.CrossRef Kuopio T, Ekfors TO, Nikkanen V, Nevalainen TJ. Acinar cell carcinoma of the pancreas. Report of three cases. APMIS. 1995;103(1):69–78.CrossRef
14.
Zurück zum Zitat Delavaud C, d'Assignies G, Cros J, Ruszniewski P, Hammel P, Levy P, et al. CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs). Eur Radiol. 2014;24(9):2128–36.CrossRef Delavaud C, d'Assignies G, Cros J, Ruszniewski P, Hammel P, Levy P, et al. CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs). Eur Radiol. 2014;24(9):2128–36.CrossRef
15.
Zurück zum Zitat Toll AD, Hruban RH, Ali SZ. Acinar cell carcinoma of the pancreas: clinical and cytomorphologic characteristics. Korean J Pathol. 2013;47(2):93–9.CrossRef Toll AD, Hruban RH, Ali SZ. Acinar cell carcinoma of the pancreas: clinical and cytomorphologic characteristics. Korean J Pathol. 2013;47(2):93–9.CrossRef
16.
Zurück zum Zitat Yoo C, Kim BJ, Kim K-P, Lee J-L, Kim TW, Ryoo B-Y, et al. Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen. Cancer Res Treat. 2017;49(3):759–65.CrossRef Yoo C, Kim BJ, Kim K-P, Lee J-L, Kim TW, Ryoo B-Y, et al. Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen. Cancer Res Treat. 2017;49(3):759–65.CrossRef
17.
Zurück zum Zitat Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12(12):2078–86.CrossRef Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12(12):2078–86.CrossRef
18.
Zurück zum Zitat Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG. Primary pancreatic cystic neoplasms of the pancreas revisited. Part IV: rare cystic neoplasms. Surg Oncol. 2012;21(3):153–63.CrossRef Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG. Primary pancreatic cystic neoplasms of the pancreas revisited. Part IV: rare cystic neoplasms. Surg Oncol. 2012;21(3):153–63.CrossRef
19.
Zurück zum Zitat Leeds JS, Nayar MN, Dawwas M, Scott J, Anderson K, Haugk B, et al. Comparison of endoscopic ultrasound and computed tomography in the assessment of pancreatic cyst size using pathology as the gold standard. Pancreatology. 2013;13(3):263–6.CrossRef Leeds JS, Nayar MN, Dawwas M, Scott J, Anderson K, Haugk B, et al. Comparison of endoscopic ultrasound and computed tomography in the assessment of pancreatic cyst size using pathology as the gold standard. Pancreatology. 2013;13(3):263–6.CrossRef
20.
Zurück zum Zitat Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, et al. Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg. 2009;13(8):1495–502.CrossRef Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, et al. Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg. 2009;13(8):1495–502.CrossRef
Metadaten
Titel
The Unusual Suspects of the Pancreas—Understanding Pancreatic Acinar Cell Carcinomas and Adenomas
verfasst von
Andreas Minh Luu
Tim Fahlbusch
Johanna Munding
Waldemar Uhl
Chris Braumann
Publikationsdatum
06.04.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00231-y

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.